Addex Therapeutics (ADXN) Fundamental Analysis: Revenue, Earnings & Valuation

6.88 / 10

Outperform

Fundamental rating is Outperform with a 6.9/10 score. Strong points include high interest coverage (15.6), positive PB‑ROE (0.31) and solid asset/revenue MV differentials. Weaknesses are steep revenue declines (~‑61%), high cost of sales (70%) and elevated liabilities (85.6%).

Analysis Checks(9/10)

Revenue-MV

Value-4.00

Score3/3

Weight31.02%

1M Return8.11%

Total operating revenue (YoY growth rate %)

Value-61.56

Score2/3

Weight0.43%

1M Return0.13%

Inventory turnover ratio

Value47.95

Score2/3

Weight-3.54%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value85.62

Score1/3

Weight-4.95%

1M Return-1.69%

PB-ROE

Value0.31

Score3/3

Weight39.08%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.17

Score2/3

Weight-1.10%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-3.60%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-61.46

Score2/3

Weight0.17%

1M Return0.05%

Cost of sales ratio (%)

Value70.31

Score2/3

Weight-3.40%

1M Return-1.13%

Asset-MV

Value-0.49

Score2/3

Weight45.88%

1M Return11.12%

Is ADXN undervalued or overvalued?

ADXN scores 6.88/10 on fundamentals and holds a Discounted valuation at present. Backed by its -62.56% ROE, -5123.22% net margin, -0.87 P/E ratio, 0.94 P/B ratio, and -265.56% earnings growth, these metrics solidify its Outperform investment rating.